Skip to main content
Veterinary Medicines

Apovomin 1 mg/ml solution for injection for dogs

Authorised
  • Apomorphine hydrochloride hemihydrate

Product identification

Medicine name:
Apovomin 1 mg/ml solution for injection for dogs
Active substance:
  • Apomorphine hydrochloride hemihydrate
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Apomorphine hydrochloride hemihydrate
    1.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN04BC07
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • Clear Type I glass vials containing 5 ml, closed with a coated Type I bromobutyl rubber stopper and sealed with an aluminium cap. Each vial is packed into a cardboard box.

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Dechra Regulatory B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Produlab Pharma B.V.
Responsible authority:
  • HPRA
Authorisation number:
  • VPA22622/002/002
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0343/001
Concerned member states:
  • Austria
  • Bulgaria
  • Croatia
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."